€2.42
The RANK ligand inhibitor denosumab as novel therapeutic agent in the spectrum of cancer bone disease
There are no reviews yet.
Your email address will not be published. Required fields are marked *
Your review *
Name *
Email *
Save my name, email, and website in this browser for the next time I comment.
Reviews
There are no reviews yet.